Patent ID: 8227477

Claim:
A crystalline Nilotinib HCl, characterized by data selected from the group consisting of: an x-ray powder diffraction pattern having peaks at about 5.7, 9.8, 15.0, 15.8 and 17.3 degrees two theta±0.2 degrees two theta, and also having peaks at about 7.5, 11.4, 18.6, 19.6 and 20.7 degrees two theta±0.2 degrees two theta; an x-ray powder diffraction pattern substantially as depicted in FIG. 19 ; an x-ray powder diffraction pattern substantially as depicted in FIG. 20 ; a solid-state 13 C NMR spectrum with signals at about 113.1, 133.1, and 160.9±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of about 9.2, 29.2 and 57.0±0.1 ppm, wherein the signal exhibiting the lowest chemical shift in the chemical shift area of 100 to 180 ppm is typically at about 103.9±1 ppm; a 13 C NMR spectrum as depicted in FIG. 21 ; a 13 C NMR spectrum as depicted in FIG. 22 ; and combinations thereof.